// App-Quantinova.ai

: An open-label, multi-center phase IIIb study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma (TREMENDOUS study).

Researchers

Presenter

  • Jia Fan

Principal Investigators

  • Shukui Qin

  • Hui-Chuan Sun

Medical Centers

  • Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

  • Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Blood/haematological Diseases

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Central Nervous System (CNS)

Disease

  • Liver cancer

  • Gastrointestinal bleeding

  • Hepatic encephalopathy

  • Encephalopathy

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Ticilimumab

  • Durvalumab

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved